|Application ||IHC-P, IF, FC|
|Other Accession||4583, 315|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Mucin-2, MUC-2, Intestinal mucin-2, MUC2, SMUC|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||MUC2 (Mucin 2) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Coats the epithelia of the intestines, airways, and other mucus membrane-containing organs. Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Major constituent of both the inner and outer mucus layers of the colon and may play a role in excluding bacteria from the inner mucus layer.|
|Cellular Location||Secreted. Note=In the intestine, secreted into the inner and outer mucus layers.|
|Tissue Location||Colon, small intestine, colonic tumors, bronchus, cervix and gall bladder|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a single glycoprotein of 520kDa, identified as mucin 2 (MUC2). This MAb shows no cross-reaction with human milk fat globule membranes, MUC1, or MUC3. Its epitope has been defined as ĀGTQTP (GlyThrGlnThrPro). Mucins are high molecular weight glycoproteins, which constitute the major component of the mucus layer that protects the gastric epithelium. MUC2 is specifically expressed in goblet cells of the small intestine & colon; in about 65% of colonic carcinomas and about 40% of gastric carcinomas. MUC2 is rarely expressed outside of the GI tract with the exceptions of mucinous carcinoma of breast and clear cell-type carcinomas of the ovary.
Xing PX, Prenzoska J, Layton GT, Devine PL, McKenzie IF. Second-generation monoclonal antibodies to intestinal MUC2 peptide reactive with colon cancer. J Natl Cancer Inst. 1992; 84(9):699-703. |
If you have any additional inquiries please email technical services at email@example.com.